CytoMed Therapeutics (GDTC) Total Debt (2021 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Total Debt for 5 consecutive years, with $315963.5 as the latest value for Q4 2025.

  • Quarterly Total Debt fell 2.7% to $315963.5 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $315963.5 through Dec 2025, down 2.7% year-over-year, with the annual reading at $313433.1 for FY2025, 0.87% down from the prior year.
  • Total Debt hit $315963.5 in Q4 2025 for CytoMed Therapeutics, down from $324737.4 in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $681482.3 in Q4 2021 to a low of $315963.5 in Q4 2025.
  • Historically, Total Debt has averaged $445678.7 across 5 years, with a median of $327162.4 in 2023.
  • Biggest five-year swings in Total Debt: plummeted 43.5% in 2023 and later decreased 0.74% in 2024.
  • Year by year, Total Debt stood at $681482.3 in 2021, then decreased by 15.03% to $579047.9 in 2022, then plummeted by 43.5% to $327162.4 in 2023, then fell by 0.74% to $324737.4 in 2024, then dropped by 2.7% to $315963.5 in 2025.
  • Business Quant data shows Total Debt for GDTC at $315963.5 in Q4 2025, $324737.4 in Q4 2024, and $327162.4 in Q4 2023.